Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Quadruplet Plus AHCT Leads to Delayed MRD Negativity but Good Outcomes in t(11;14) MM Free
Thomas R. Collins
December 16, 2025
Cancer-Specific Risk Assessment Model Better at Predicting Hospital-Acquired VTE Free
Leah Lawrence
December 15, 2025
Study Identifies Potential Surrogate Marker for Bleeding Risk in AHA with Emicizumab Free
Ruth Jessen Hickman, MD
December 15, 2025
Vigilance Needed to Prevent Hemolytic Events When Switching Complement Inhibitors in PNH Free
Ruth Jessen Hickman, MD
December 12, 2025
Bifunctional Monoclonal Antibody for PNH Continues to Show Positive Results Free
Ruth Jessen Hickman, MD
December 12, 2025
siRNA Successfully Targets Complement Factor B in PNH Free
Ruth Jessen Hickman, MD
December 12, 2025
Risk Factors for Renal Dysfunction in PV Identified Free
Thomas R. Collins
December 10, 2025
PATHFINDER Four-Year Update: Avapritinib Continues to Deliver Durable, Deep Responses in Advanced Systemic Mastocytosis Free
Pinky Sharma
December 10, 2025
Bezuclastinib Improves Symptoms, Biomarkers in Nonadvanced Systemic Mastocytosis Free
Pinky Sharma
December 10, 2025
Bezuclastinib Improves Disease Pathology of Systemic Mastocytosis in Phase II Trial Free
Anna Azvolinsky, PhD
December 10, 2025
KRd Regimen Achieves Superior Efficacy Over VRd in NDMM Phase III Trial Free
Anna Azvolinsky, PhD
December 10, 2025
Antibody-Based Doublet Effective in Elderly Patients with NDMM Free
Leah Lawrence
December 10, 2025
ROSEWOOD Final Analysis: Combination Zanubrutinib-Obinutuzumab Improves Outcomes Over Obinutuzumab Alone in R/R FL Free
Khylia Marshall
December 9, 2025
Fixed-Duration Mosunetuzumab with Lenalidomide Has Benefits for Untreated Indolent Lymphomas Free
Leah Lawrence
December 9, 2025
Mosunetuzumab Shows Safety, Efficacy as Frontline Therapy in High Tumor Buden Follicular Lymphoma Free
Khylia Marshall
December 9, 2025
Next-Gen BCL2 Inhibitor Sonrotoclax Shows Good Outcomes in Phase I Trial Free
Thomas R. Collins
December 2, 2025
Zanubrutinib, Obinutuzumab, Sonrotoclax Combo Shows Positive Outcomes for Treatment-Naïve CLL Free
Leah Lawrence
December 2, 2025
Head-To-Head Data Strong for Pirtobrutinib Over Ibrutinib Free
Thomas R. Collins
December 2, 2025
Lisaftoclax Achieves Objective Response Primary Endpoint in Phase II R/R CLL Trial Free
Anna Azvolinsky, PhD
December 2, 2025
Fully Human BCMA-Targeting CAR T-Cell Therapy Eque-Cel May Be Effective in High-Risk NDMM Free
Leah Lawrence
December 2, 2025

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
December 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals